

January 29, 2025

PRIOR AUTHORIZATION UPDATES FOR MARKETPLACE AND D-SNP- EFFECTIVE APRIL 1, 2025

SUMMARY OF NOTIFICATION

On April 1, 2025, Rytelo (imetelstat) J0870 will be added to the prior authorization catalog for Marketplace and Medicare.

Skyrizi (Risankizumab-rzaa) J2327 will be added to the prior authorization catalog for Marketplace.

Clinician Administered Drugs - Site of Care Medical Review Guideline will be implemented for Marketplace.

KEY DETAILS

Please refer to the Marketplace and Medicare prior authorization catalog effective April 1, 2025 on our [Community provider website](#) for the complete list.

For the Site of Care Medical Review guideline, you can view the updates on our [Community provider website](#) under the “Prior Authorization Requests: Essential Information & Supporting Clinical Documentation” section. The guideline will require specific, clinician administered products to be administered in non-hospital based sites.